Centre for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya; Paul G Allen School for Global Health, Washington State University, Pullman, WA, USA.
MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK; London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
Lancet Glob Health. 2024 May;12(5):e771-e782. doi: 10.1016/S2214-109X(24)00043-3. Epub 2024 Mar 11.
WHO has proposed elimination of transmission of onchocerciasis (river blindness) by 2030. More than 99% of cases of onchocerciasis are in sub-Saharan Africa. Vector control and mass drug administration of ivermectin have been the main interventions for many years, with varying success. We aimed to identify factors associated with elimination of onchocerciasis transmission in sub-Saharan Africa.
For this systematic review and meta-analysis we searched for published articles reporting epidemiological or entomological assessments of onchocerciasis transmission status in sub-Saharan Africa, with or without vector control. We searched MEDLINE, PubMed, Web of Science, Embase, Cochrane Central Register of Controlled Trials, African Index Medicus, and Google Scholar databases for all articles published from database inception to Aug 19, 2023, without language restrictions. The search terms used were "onchocerciasis" AND "ivermectin" AND "mass drug administration". The three inclusion criteria were (1) focus or foci located in Africa, (2) reporting of elimination of transmission or at least 10 years of ivermectin mass drug administration in the focus or foci, and (3) inclusion of at least one of the following assessments: microfilarial prevalence, nodule prevalence, Ov16 antibody seroprevalence, and blackfly infectivity prevalence. Epidemiological modelling studies and reviews were excluded. Four reviewers (NM, AJ, AM, and TNK) extracted data in duplicate from the full-text articles using a data extraction tool developed in Excel with columns recording the data of interest to be extracted, and a column where important comments for each study could be highlighted. We did not request any individual-level data from authors. Foci were classified as achieving elimination of transmission, being close to elimination of transmission, or with ongoing transmission. We used mixed-effects meta-regression models to identify factors associated with transmission status. This study is registered in PROSPERO, CRD42022338986.
Of 1525 articles screened after the removal of duplicates, 75 provided 282 records from 238 distinct foci in 19 (70%) of the 27 onchocerciasis-endemic countries in sub-Saharan Africa. Elimination of transmission was reported in 24 (9%) records, being close to elimination of transmission in 86 (30%) records, and ongoing transmission in 172 (61%) records. I was 83·3% (95% CI 79·7 to 86·3). Records reporting 10 or more years of continuous mass drug administration with 80% or more therapeutic coverage of the eligible population yielded significantly higher odds of achieving elimination of transmission (log-odds 8·5 [95% CI 3·5 to 13·5]) or elimination and being close to elimination of transmission (42·4 [18·7 to 66·1]) than those with no years achieving 80% coverage or more. Reporting 15-19 years of ivermectin mass drug administration (22·7 [17·2 to 28·2]) and biannual treatment (43·3 [27·2 to 59·3]) were positively associated with elimination and being close to elimination of transmission compared with less than 15 years and no biannual mass drug administration, respectively. Having had vector control without vector elimination (-42·8 [-59·1 to -26·5]) and baseline holoendemicity (-41·97 [-60·6 to -23·2]) were associated with increased risk of ongoing transmission compared with no vector control and hypoendemicity, respectively. Blackfly disappearance due to vector control or environmental change contributed to elimination of transmission.
Mass drug administration duration, frequency, and coverage; baseline endemicity; and vector elimination or disappearance are important determinants of elimination of onchocerciasis transmission in sub-Saharan Africa. Our findings underscore the importance of improving and sustaining high therapeutic coverage and increasing treatment frequency if countries are to achieve elimination of onchocerciasis transmission.
The Bill & Melinda Gates Foundation and Neglected Tropical Diseases Modelling Consortium, UK Medical Research Council, and Global Health EDCTP3 Joint Undertaking.
For the Swahili, French, Spanish and Portuguese translations of the abstract see Supplementary Materials section.
世界卫生组织(WHO)提议到 2030 年消除(河盲症)盘尾丝虫病的传播。超过 99%的盘尾丝虫病病例都在撒哈拉以南非洲。多年来,控制传播媒介和大规模药物治疗伊维菌素一直是主要干预措施,但效果不一。我们旨在确定与撒哈拉以南非洲消除盘尾丝虫病传播相关的因素。
为了进行这项系统评价和荟萃分析,我们搜索了已发表的文章,这些文章报告了撒哈拉以南非洲盘尾丝虫病传播状况的流行病学或昆虫学评估,无论是否有传播媒介控制。我们在 MEDLINE、PubMed、Web of Science、Embase、Cochrane 对照试验中心注册库、非洲医学索引和 Google Scholar 数据库中搜索了从数据库成立到 2023 年 8 月 19 日发表的所有文章,没有语言限制。使用的搜索词是“盘尾丝虫病”和“伊维菌素”和“大规模药物治疗”。三个纳入标准是:(1)重点或焦点位于非洲;(2)报告传播已消除或在重点或焦点中至少进行了 10 年的伊维菌素大规模药物治疗;(3)包括以下至少一项评估:微丝蚴患病率、结节患病率、 Ov16 抗体血清阳性率和蚋感染率。排除了流行病学建模研究和综述。四名审查员(NM、AJ、AM 和 TNK)使用在 Excel 中开发的数据提取工具从全文文章中重复提取数据,该工具列有要提取的数据以及可以突出显示每个研究的重要评论的列。我们没有向作者请求任何个人层面的数据。将焦点分为传播已消除、接近消除或仍在传播。我们使用混合效应荟萃回归模型来确定与传播状况相关的因素。本研究已在 PROSPERO 注册,CRD42022338986。
在去除重复项后筛选出的 1525 篇文章中,有 75 篇提供了 238 个焦点的 282 个记录,分布在撒哈拉以南非洲 27 个盘尾丝虫病流行国家中的 19 个国家。报告传播已消除的有 24 个记录,接近消除的有 86 个记录,仍在传播的有 172 个记录。伊维菌素的总有效率为 83.3%(95%CI 79.7 至 86.3)。报告 10 年或以上连续大规模药物治疗,并有 80%或以上的合格人口接受治疗的记录,其实现传播消除或接近消除的几率显著更高(对数优势比 8.5 [95%CI 3.5 至 13.5])或消除和接近消除(42.4 [18.7 至 66.1])比那些没有 80%覆盖率或以上的记录。报告伊维菌素大规模药物治疗 15-19 年(22.7 [17.2 至 28.2])和每半年治疗一次(43.3 [27.2 至 59.3])与少于 15 年和没有半年一次的大规模药物治疗相比,与消除和接近消除有关。有传播媒介控制而没有消除传播媒介(-42.8 [-59.1 至 -26.5])和基线全流行(-41.97 [-60.6 至 -23.2])与没有传播媒介控制和低流行相比,传播持续存在的风险增加。由于传播媒介控制或环境变化导致蚋消失有助于传播的消除。
大规模药物治疗的持续时间、频率和覆盖范围;基线流行程度;以及传播媒介的消除或消失是撒哈拉以南非洲消除盘尾丝虫病传播的重要决定因素。我们的研究结果强调了提高和维持高治疗覆盖率以及增加治疗频率的重要性,如果各国要实现盘尾丝虫病传播的消除。
比尔和梅林达·盖茨基金会和被忽视的热带病建模联盟、英国医学研究理事会和全球卫生 EDCTP3 联合倡议。